CRSP

Rating neutralAI MemoPost-earnings T+3

CRISPR Therapeutics

As of 2026-08-13/Post-earnings T+3/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-08-13 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

neutral

Confidence

medium

Horizon

—

Key catalyst

Q2 results and Casgevy expansion • 2026-08-03

Base target: $59 / p=1% prob

Biggest risk

Casgevy commercialization remains dependent on Vertex-led execution, treatment capacity, reimbursement, and broader access. Most pipeline value remains clinically unproven, so disappointing safety or efficacy data could outweigh commercial progress. No reliable post-print analyst revision or target-change set is available.

Invalidation

Break below $38 or thesis failure.

What would change my mind?

Casgevy adoption is accelerating, pediatric expansion broadens the eligible population, and upcoming CTX310, CTX340, CTX460, and zugo-cel data create several potential re-rating points. Secondary coverage reported Q2 EPS of negative $0.94 versus a negative $1.10 consensus estimate and revenue of $10.2 million versus $7 million consensus. [#PR-EARNINGS-2026-08-04]

Research note

Recommendation

neutral

Confidence

medium

As of

2026-08-13

Base target

$59

p=1%

Bull target

$82

p=0%

Bear target

$38

p=0%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Second-half clinical pipeline execution
Casgevy adoption is accelerating, pediatric expansion broadens the eligible population, and upcoming CTX310, CTX340, CTX460, and zugo-cel data create several potential re-rating points.
Secondary coverage reported Q2 EPS of negative $0.94 versus a negative $1.10 consensus estimate and revenue of $10.2 million versus $7 million consensus.

BearKey bullets

Casgevy uptake may be constrained by reimbursement, manufacturing, treatment-center capacity, or Vertex execution.
Clinical, safety, regulatory, and enrollment risk across CTX310, CTX340, CTX460, and zugo-cel.
No dependable analyst estimate revisions, target changes, or clean post-earnings market-reaction attribution are available in the packet.

WatchKey bullets

Q2 results and Casgevy expansion

Summary

High-level snapshot

Recommendation

neutral

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Post-earnings T+3

Base case: $59 (p=1%)

Target spread vs base: +39% / -36%

Scenario probabilities

Bull Target: $82 (p=0%)Base Target: $59 (p=1%)Bear Target: $38 (p=0%)

Commentary

Post-earnings coverage is mildly constructive because of Casgevy growth and multiple second-half milestones, but the packet lacks robust analyst-revision data and social coverage. One Form 4 reported a chief medical officer open-market sale of 3,786 shares, which is not evidence of operating performance. [#SEC-FORM4-2026-06-01]

As of 2026-08-13 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Second-half clinical pipeline execution

Scenarios

Bull Target (Scenario probability)

$82 / p=0% prob

Base Target (Scenario probability)

$59 / p=1% prob

Bear Target (Scenario probability)

$38 / p=0% prob

Analysis 2026-08-13 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.10

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-08-03
Q2 results and Casgevy expansion
The August 3 8-K reported $76 million of Q2 Casgevy revenue, up 78% quarter over quarter and 151% year over year, alongside FDA approval for patients aged two and older. Secondary earnings coverage characterized Q2 EPS and revenue as ahead of consensus. [#SEC-8K-2026-08-03] [#PR-EARNINGS-2026-08-04]
Prob 100.00% • Move 3.00% • Priced-in 80.00%
EVENT2026-08-28
CTX310 durability data at ESC Congress
A late-breaking CTX310 durability abstract is scheduled for presentation at the European Society of Cardiology Congress, with a Phase 1a update expected; the company also expects a Phase 1b update in the second half of 2026. [#SEC-8K-2026-08-03]
Prob 65.00% • Move 8.00% • Priced-in 35.00%

Short-term Catalysts

Next few weeks

No short-term catalysts

Long-term Catalysts

Months to a year

Second-half clinical pipeline execution
2027-08-13
CRSP has initiated Phase 1 studies for CTX340 in refractory hypertension and CTX460 in alpha-1 antitrypsin deficiency, while zugo-cel autoimmune studies continue. The value impact remains dependent on enrollment, safety, and early efficacy data. [#SEC-8K-2026-08-03]
Prob 55% • Move 15% • Priced-in 30%

Risks

Casgevy uptake may be constrained by reimbursement, manufacturing, treatment-center capacity, or Vertex execution.
Clinical, safety, regulatory, and enrollment risk across CTX310, CTX340, CTX460, and zugo-cel.
No dependable analyst estimate revisions, target changes, or clean post-earnings market-reaction attribution are available in the packet.
Ongoing R&D and collaboration spending can reduce the cash runway before pipeline programs generate meaningful revenue.

Peers

Symbol	Summary
DYN	Mid-cap clinical-stage biotech with platform and development risk; a useful volatility comparator, but its programs and indications differ materially from CRSP.
EWTX	Mid-cap clinical-stage biotechnology peer with comparable binary-readout exposure, though it is not a direct commercial or gene-editing comparable.
ACAD	Same-sector commercial biopharma comparator; useful for commercialization context, but its CNS-focused portfolio is materially different.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-08-13

Loading AI feed…

Symbol

Summary

DYN

Mid-cap clinical-stage biotech with platform and development risk; a useful volatility comparator, but its programs and indications differ materially from CRSP.

EWTX

Mid-cap clinical-stage biotechnology peer with comparable binary-readout exposure, though it is not a direct commercial or gene-editing comparable.

ACAD

Same-sector commercial biopharma comparator; useful for commercialization context, but its CNS-focused portfolio is materially different.